|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, November 09, 2017 ) Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia-Pipeline Review, H2 2017, provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape.
Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. Risk factors include family history, age, drugs (psychoactive) and weakened immune system. Treatment includes antipsychotic medications.
Report Highlights
Publisher's Pharmaceutical and Healthcare latest pipeline guide Schizophrenia-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Schizophrenia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 13, 13, 18, 1, 61, 9 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 8 and 2 molecules, respectively.
Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis
Request Free Sample Copy at http://www.reportsweb.com/inquiry&RW00011199438/sample
Report Scope
-The pipeline guide provides a snapshot of the global therapeutic landscape of Schizophrenia (Central Nervous System).
-The pipeline guide reviews pipeline therapeutics for Schizophrenia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
-The pipeline guide reviews key companies involved in Schizophrenia (Central Nervous System) therapeutics and enlists all their major and minor projects.
-The pipeline guide evaluates Schizophrenia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
-The pipeline guide reviews latest news related to pipeline therapeutics for Schizophrenia (Central Nervous System)
For more information about this report http://www.reportsweb.com/schizophrenia-pipeline-review-h2-2017
Reasons to buy
Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Find and recognize significant and varied types of therapeutics under development for Schizophrenia (Central Nervous System).
-Classify potential new clients or partners in the target demographic.
-Develop tactical initiatives by understanding the focus areas of leading companies.
-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
-Formulate corrective measures for pipeline projects by understanding Schizophrenia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
-Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Company Profile
Acadia Pharmaceuticals Inc
Adamed Sp z oo
Aequus Pharmaceuticals Inc
AgeneBio Inc
Alkermes Plc
Astellas Pharma Inc
Athersys Inc
Avanir Pharmaceuticals Inc
Avineuro Pharmaceuticals Inc
BCWorld Pharm Co Ltd
BioCrea GmbH
BioHealthonomics Inc
Boehringer Ingelheim GmbH
Braeburn Pharmaceuticals Inc
Bristol-Myers Squibb Co
Curemark LLC
Daewoong Pharmaceutical Co Ltd
Delpor Inc
Denovo Biopharma LLC
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
